FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

	OMB APP	PROVA	
OMMEDOLUB	OMB Number:	3235	

3235-0287 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Estimated average burden

hours per response:

0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

			or occitor oo(ii) or the investment company Act or 1040	
1. Name and Address of Reporting Person* Fletcher Aaron G.L. (Last) (First) (Middle)			2. Issuer Name and Ticker or Trading Symbol COGNITION THERAPEUTICS INC CGTX	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner Officer (give title Other (specify below) below)
	C/O BIOS EQUITY PARTNERS 751 RIVER RUN, SUITE 400		3. Date of Earliest Transaction (Month/Day/Year) 11/15/2022	
(Street) FORT WOI	RTH, TX (State)	76107 (Zip)	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person X Form filed by More than One Reporting Person
	_			

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned										
1. Title of Security (Instr. 3)	curity (Instr. 3) 2. Transaction Date (Month/Day/Year) 2. Transaction Date (Month/Day/Year) 2. Transaction Date (Instruction Date) (Month/Day/Year) 2. Transaction Date (Instruction Date) (Month/Day/Year)		iction Instr.	4. Securities A Disposed Of (5)	Acquired D) (Instr.	(A) or . 3, 4 and	5. Amount of Securities Beneficially Owned Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership	
			Code	v	Amount	(A) or (D)	Price	Reported Transaction(s) (Instr. 3 and 4)		(Instr. 4)
Common Stock	11/15/2022		Р	V	184,270	A	\$1.2	316,038	I	By Bios Fund III NT, LP ⁽¹⁾ (2)(3)(4)
Common Stock	11/15/2022		P	v	1,141,030	A	\$1.2	1,955,677	I	By Bios Fund III QP, LP ⁽¹⁾ (2)(3)(4)
Common Stock	11/15/2022		P	v	174,700	A	\$1.2	299,608	I	Bios Fund III, LP ⁽¹⁾⁽²⁾
Common Stock								1,424,014	I	By Bios Memory SPV I, LP ⁽¹⁾⁽²⁾⁽³⁾⁽⁴⁾
Common Stock								418,926	I	By: Bios Fund I, LP ⁽¹⁾⁽²⁾⁽³⁾⁽⁴⁾
Common Stock								245,029	I	By: Bios Fund I QP, LP ⁽¹⁾ (2)(3)(4)
Common Stock								78,298	I	By: Bios Fund II, LP ⁽¹⁾⁽²⁾⁽³⁾⁽⁴⁾
Common Stock								255,765	I	By: Bios Fund II QP, LP ⁽¹⁾ (2)(3)(4)
Common Stock								34,238	I	By: Bios Fund II NT, LP ⁽¹⁾ (2)(3)(4)
Common Stock								385,248	I	By Bios Memory SPV II, LP ⁽¹⁾⁽²⁾⁽³⁾⁽⁴⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of	Date (Month/Day/Year)	FA-IPee Dedrivat Execution Date, if any (e.g., pu (Month/Day/Year)	Trans ItSo,d6	ecui action als:	riti es , w ar i	ARCOTU Ants, urities	Expiration Day/ Expiration Day/ OpplionDay/	osetiaof, dans de la composition della composition de la composition de la composition della compositi	162 eg C	អាមពីcial _{Int of} Qម៖ities _{rlying}	Derivative	9. Number of derivative Securities	10. Ownership Form: Direct (D)
Derivative Security		(Monumbay/rear)	0)		Acq (A) o Disp of (E	uired or oosed O) tr. 3, 4			Deriv	ative rity (Instr. I 4)	(ilisti. 5)	Owned Following Reported Transaction(s) (Instr. 4)	or Indirect (I) (Instr. 4)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Trans Code §ode	(Instr	n of Deri \$Asc	umber vative uritles	6. Date Exerc Expiration Da (Menth/Day/) Exercisable	te eExpiration	Secu UiAld e	-ışihares	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially	10. Ownership Form: Direct (D)
1. Name and ACHIESS of Fletcher Aaron					(A) C Disp of (E	oosed D) tr. 3, 4			Deriv Secu 3 and	rity (Instr.		Owned Following Reported Transaction(s) (Instr. 4)	or Indirect (I) (Instr. 4)
(Last) C/O BIOS EQUITY 1751 RIVER RUN,	1	(Middle)	Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
(Street) FORT WORTH,	TX	76107	*		•								
(City)	(State)	(Zip)		_									
1. Name and Address o BIOS Capital M	, ,	<u>.P</u>											
(Last) 1751 RIVER RUN SUITE 400	(First)	(Middle)											
(Street) FORT WORTH	TX	76107											
(City)	(State)	(Zip)											
1. Name and Address o BIOS Advisors													
(Last) 1751 RIVER RUN SUITE 400	(First)	(Middle)											
(Street) FORT WORTH	TX	76107		_									
(City)	(State)	(Zip)											
1. Name and Address o Bios Equity Par													
(Last) 1751 RIVER RUN SUITE 400	(First)	(Middle)											
(Street)	TX	76107		- [
FORT WORTH													

(Last)

(City)

1751 RIVER RUN SUITE 400

FORT WORTH

(First)

TX

(State)

(Middle)

76107

(Zip)

11. Nature of Indirect Beneficial Ownership (Instr. 4)

11. Nature of Indirect Beneficial Ownership (Instr. 4)

1. Name and Address BIOS Fund I Q	· -					
(Last) 1751 RIVER RUN SUITE 400	(First)	(Middle)				
(Street) FORT WORTH	TX	76107				
(City)	(State)	(Zip)				
1. Name and Address BIOS Memory	· -					
(Last) 1751 RIVER RUN SUITE 400	(First)	(Middle)				
(Street) FORT WORTH	TX	76107				
(City)	(State)	(Zip)				
1. Name and Address Bios Equity Par						
(Last) C/O BIOS EQUIT 1751 RIVER RUN		(Middle)				
(Street) FORT WORTH	TX	76107				
(City)	(State)	(Zip)				
1. Name and Address BIOS Fund II,						
(Last) 1751 RIVER RUN SUITE 140	(First)	(Middle)				
(Street) FORT WORTH	TX	76107				
(City)	(State)	(Zip)				
1. Name and Address of Reporting Person* BIOS Fund II QP, LP						
(Last) C/O BIOS EQUIT 1751 RIVER RUN		(Middle)				
(Street) FORT WORTH	TX	76107				
(City)	(State)	(Zip)				

Explanation of Responses:

Remarks:

^{1.} Bios Equity Partners, LP ("Bios Equity I") is the general partner of the following entities: Bios Fund I, LP ("Bios Fund I QP, LP ("Bios Fund I QP") and Bios Memory SPV I, LP ("Bios Memory I"). Bios Equity Partners II, LP ("Bios Equity II") is the general partner of the following entities: Bios Fund II, LP ("Bios Fund II QP, LP ("Bios Fund II QP"), Bios Fund II NT, LP ("Bios Fund II NT") and Bios Memory SPV II, LP ("Bios Memory II"). Bios Equity Partners III, LP ("Bios Equity III") is the general partner of the following entities: Bios Fund III, LP ("Bios Fund III NT") and Bios Memory SPV II, LP ("Bios Memory II"). Bios Equity Partners III, LP ("Bios Equity III") is the general partner of the following entities: Bios Fund III, LP ("Bios Fund III"), Bios Fund III QP, LP ("Bios Management") and Cavu Management, LP ("Cavu Management") are the general partners Bios Equity III. Bios Advisors GP, LLC ("Bios Advisors") is the general partner of Bios Management. Cavu Advisors LLC ("Cavu Advisors") is the general partner of Cavu Management.

^{2.} Bios Management and Bios Advisors are entities managed and controlled by Aaron G.L. Fletcher. Cavu Management and Cavu Advisors are entities managed and controlled by Leslie W. Kreis, Jr.

^{3.} Mr. Kries, Cavu Management, Cavu Advisors, Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund I, Bios Fund I QP, Bios Memory SPV I, Bios Fund II, Bios Fund II QP, Bios Fund II QP, Bios Fund II NT, Bios Memory II, Bios Fund III QP and Bios Fund III NT (collectively, the "Bios Equity Entities"). Because of the relationship between Mr. Kries, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors, Bios Advisors and the Bios Equity Entities, Mr. Kries, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors, and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities.

^{4.} For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.

/s/ Aaron G.L. Fletcher 11/16/2022 Bios Capital Management, LP By: Bios Advisors GP, LLC, 11/16/2022 its general partner By: /s/ Aaron Glenn Louis Fletcher, <u>Manager</u> Bios Advisors GP, LLC By: /s/ Aaron Glenn Louis 11/16/2022 Fletcher, Manager Bios Equity Partners, LP By: Bios Capital Management, LP, its general partner By: Bios 11/16/2022 Advisors GP, LLC, its general partner By: /s/ Aaron Glenn Louis Fletcher, Manager Bios Fund I, LP By: Bios Equity Partners, LP, its general partner By: Bios Capital Management, LP, its general 11/16/2022 partner By: Bios Advisors GP, LLC, its general partner By: /s/ Aaron Glenn Louis Fletcher, Manager Bios Fund I QP, LP By: Bios Equity Partners, LP, its general partner By: Bios Capital Management, LP, its general 11/16/2022 partner By: Bios Advisors GP, LLC, its general partner By: /s/ Aaron Glenn Louis Fletcher, Manager Bios Memory SPV I, LP By: Bios Capital Management, LP, its general partner By: Bios 11/16/2022 Advisors GP, LLC, its general partner By: /s/ Aaron Glenn Louis Fletcher, Manager Bios Equity Partners II, LP By: Bios Capital Management, LP, its general partner By: Bios Advisors GP, 11/16/2022 LLC, its general partner By: /s/ Aaron Glenn Louis Fletcher, Manager Bios Fund II, LP By: Bios Equity Partners II, LP, its general partner By: Bios Capital Management, LP, its 11/16/2022 general partner By: Bios Advisors GP, LLC, its general partner By: /s/ Aaron Glenn Louis Fletcher, Manager Bios Fund II QP, LP By: Bios Equity Partners II, LP, its general partner By: Bios Capital Management, LP, its 11/16/2022 general partner By: Bios Advisors GP, LLC, its general partner By: /s/ Aaron Glenn Louis Fletcher, Manager ** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

^{*} If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

^{**} Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).